During Wednesday’s trade, Shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX), lost -4.58% to $39.49.
Pacira Pharmaceuticals, declared that James S. Scibetta has been designated president, effective October 20, 2015. In this capacity, Mr. Scibetta will oversee the day-to-day operations and tactical execution of the Company’s newly formed Customer and Patient Solutions (CPS) group, comprised of its customer-facing resources. He will also continue to oversee the Pacira Science Center Campus (SCC) activities.
Mr. Scibetta will continue to report to Chief Executive Officer and Chairman Dave Stack, who will maintain oversight of the commercial and corporate strategy. Mr. Stack will also continue to lead the development program for the expanded use of EXPAREL (bupivacaine liposome injectable suspension) and the DepoFoam pipeline of products, in addition to business operations and performance.
“Jim is a proven leader with demonstrated excellence in organizational efficiency to optimize results, and has been instrumental in accelerating the growth of Pacira,” said Mr. Stack. “This important evolution of senior administration allows me the opportunity to place renewed focus on product strategy and long-term value driving opportunities for the Company and affords me the ability to more closely interface with our customers again. I look forward to ongoing to advance our corporate mission to improve patient care by providing an innovative non-opioid option like EXPAREL to as many postsurgical patients as appropriate.”
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
Shares of ConAgra Foods Inc (NYSE:CAG), inclined 0.24% to $41.17, during its current trading session.
Marie Callender’s, declared the return of the Comforts From Home Project, a partnership with the United Service Organizations (USO) that’s committed to bringing the heartwarming feelings, flavors, and favorites of home to those who miss it most. In its second year, the Comforts From Home Project invites consumers to support USO Operation Celebration™, a program dedicated to celebrating holidays and other special occasions for service members and military families who are missing the comforts of home during these special times. The program brings food, decorations and games to USO locations around the world so that our nation’s military community can celebrate special occasions no matter where they are serving.
From September 1, 2015 through January 29, 2016, consumers can assist give to USO Operation Celebration by entering the on-pack code from one of the more than about 55 million specially marked packages of Marie Callender’s frozen meals or desserts at www.ComfortsFromHome.com. Marie Callender’s will donate $.50 to USO Operation Celebration for each code entered.
“Last year, with consumers’ overwhelming support, Marie Callender’s brought care packages to a very deserving group of servicemen and women stationed overseas through a $250,000 donation to the USO2GO program,” said Christiane Brocky, vice president and general manager, ConAgra Foods. “This year, we’re proud to support USO Operation Celebration to assist bring a taste of home and its comforts to our troops when their service takes them away from family and friends during the holidays and other special occasions.”
ConAgra Foods, Inc. operates as a food company primarily in North America. The company operates through three segments: Consumer Foods, Commercial Foods, and Private Brands. The Consumer Foods segment provides branded food products in various categories, such as meals, entrees, condiments, sides, snacks, and desserts to various retail channels, such as frozen, refrigerated, and shelf-stable temperature classes.
Finally, Shares of Relypsa Inc (NASDAQ:RLYP), gained 0.60%, and is now trading at $16.78.
Relypsa, declared that on October 15, 2015, the compensation committee of the company’s board of directors granted nine new employees options to purchase an aggregate of 21,500 shares of the company’s common stock with a per share exercise price of $19.50, the closing trading price on the grant date, and 10,750 restricted stock units. The stock options and restricted stock units were granted following the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
Relypsa, Inc., a biopharmaceutical company, focuses on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular, and metabolic diseases in the United States.
